These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 16716150)

  • 1. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in treatment-resistant autoimmune blistering skin disorders.
    Schmidt E; Bröcker EB; Goebeler M
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
    Kasperkiewicz M; Zillikens D
    Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
    Wallet-Faber N; Franck N; Batteux F; Mateus C; Gilbert D; Carlotti A; Avril MF; Dupin N
    Dermatology; 2007; 215(3):252-5. PubMed ID: 17823525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
    Li Y; Foshee JB; Sontheimer RD
    J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).
    Niedermeier A; Eming R; Pfütze M; Neumann CR; Happel C; Reich K; Hertl M
    Arch Dermatol; 2007 Feb; 143(2):192-8. PubMed ID: 17309999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
    Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
    J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment of autoimmune blistering diseases.
    Kasperkiewicz M; Schmidt E
    Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous autoimmune dermatoses.
    Hofmann SC; Juratli HA; Eming R
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.
    Schmidt E; Seitz CS; Benoit S; Bröcker EB; Goebeler M
    Br J Dermatol; 2007 Feb; 156(2):352-6. PubMed ID: 17223877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autoimmune bullous skin disorders].
    Hertl M; Niedermeier A; Borradori L
    Ther Umsch; 2010 Sep; 67(9):465-82. PubMed ID: 20806175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in dermatological diseases.
    Troiano M; Lotti T
    G Ital Dermatol Venereol; 2009 Aug; 144(4):495-9. PubMed ID: 19755955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z; Tchen T; Perceau G; Bernard P
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
    Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.